AstraZeneca Announces $50 Billion Additional Investment in U.S. Manufacturing and R&D Through 2030

On July 21, AstraZeneca announced that it would invest $50 billion in the U.S. market by 2030 to further solidify the United States' global leadership in pharmaceutical manufacturing and research and development. This investment is expected to create tens of thousands of high-skilled jobs directly or indirectly and provide next-generation medicines for patients in the U.S. and around the world.

The core project of this investment is AstraZeneca's plan to build a new active pharmaceutical ingredient (API) manufacturing plant worth billions of dollars in Virginia, USA. The plant will be used to produce the company's product lines for weight management and innovative drugs for metabolic diseases, including oral GLP-1, Baxdrostat, oral PCSK9, and small molecule combination products.

The factory will have the production capacity for small molecules, peptides, and oligonucleotides, and will extensively utilize artificial intelligence, automation, and data analysis to optimize production capacity. This multi-billion-dollar investment complements AstraZeneca's $3.5 billion investment announced in November 2024.

According to the announcement, the Virginia plant will become AstraZeneca's largest single manufacturing investment project globally. With the completion of this plant, the medicines sold by AstraZeneca in the U.S. market will be largely produced domestically.

In addition to the construction of the factory, the $50 billion investment will also be used for the following purposes over the next five years:

· Expand the R&D center located in Gaithersburg, Maryland

· Establish an advanced R&D center located in Kendall Square, Cambridge, Massachusetts

· Establishment of next-generation cell therapy manufacturing facilities located in Rockville, Maryland, and Tarzana, California.

· Expansion of the continuous production plant in Vernon, Indiana

· Expand the professional manufacturing production line in Coppell, Texas

· New Base for Clinical Trials Added

· Continuously increase investment in new drug development

AstraZeneca CEO Pascal Soriot, in response to the tariff policy, stated, "The localization of pharmaceutical production has become a national security issue, which aligns with the government's vision, and the tariff policy has accelerated our existing layout process." Despite his previous call for tax incentives to replace tariffs, in the face of policy realities, the company has chosen to adapt to the changing winds by implementing capacity transfers.

AstraZeneca's 2024 financial report shows that the U.S. market accounts for more than 40% of AstraZeneca's annual revenue, making it the company's largest single market globally. AstraZeneca has 19 R&D, manufacturing, and commercial bases in the U.S., with over 18,000 employees, supporting 92,000 jobs.

In November 2024, AstraZeneca announced a $3.5 billion investment in the United States through the end of 2026, at which time it disclosed that it had nearly 18,000 employees in the U.S., accounting for 20% of its global workforce of 90,000. The newly announced $50 billion investment is a supplementary upgrade to the previous plan and will support AstraZeneca's strategic goal of achieving $80 billion in total revenue by 2030, with 50% coming from the U.S. market.

Although pharmaceuticals have not yet been included in Trump's tariff list, the industry generally anticipates an impending policy change. AstraZeneca's recently announced $50 billion investment plan is a direct result of the growing tariff pressure from the Trump administration.

On July 8, Trump publicly stated: "Drugs may face tariffs of up to 200%," but indicated that pharmaceutical companies would have at least one year to move their operations back to the United States. U.S. Commerce Secretary Luthnick subsequently confirmed that details of the drug tariffs would be announced by the end of July.

Against this backdrop, MNCs have collectively announced expansions in U.S. investments and capacity building, initiating an unprecedented migration of production capacity:

In March 2025, Eli Lilly announced an investment of $27 billion to build four new manufacturing plants in the United States, focusing on metabolic disease products such as GLP-1; AbbVie stated plans to invest $10 billion in the U.S. over the next decade to expand capacity for anti-inflammatory and immunology products; Roche announced a $50 billion investment in the U.S. over the next five years, creating more than 12,000 jobs to advance domestic biopharmaceutical manufacturing.

In April, Novartis announced a $23 billion investment in the United States over the next five years to promote the "Made in America" initiative for key drugs; Amgen announced a $900 million expansion of manufacturing facilities in the U.S. to support antibody drugs and cell therapies.

In May, Sanofi announced a plan to invest no less than 20 billion US dollars in the United States by 2030;

In July, AstraZeneca announced a total investment of $50 billion in the U.S. by 2030, with the establishment of the world's largest API production base in Virginia, focusing on key production lines including GLP-1, small molecules, and oligonucleotides; Biogen announced an additional investment of $2 billion in North Carolina, further expanding its domestic manufacturing capabilities, among others.

The Core Logic of MNCs Expanding Investment in the U.S.: Avoiding Tariff Costs, Accessing Key Markets, and Meeting Localization Political Demands. This ensures the production and supply of critical products can be carried out locally in the U.S., reducing reliance on overseas supply chains, enhancing the stability and reliability of the supply chain, thereby cutting costs and boosting competitiveness.

But this capacity migration also faces structural challenges. First, most MNCs’ committed investment period is five years, while building a new factory that meets FDA standards takes 4-5 years, far exceeding the one to one-and-a-half-year buffer period given by Trump. Second, increased tariffs on medicines will also drive up U.S. drug prices, and a 200% tariff could lead to a shortage crisis for generic drugs. At the same time, the production of high-end biologics relies on Asia's mature supply chain, which cannot be fully replaced by newly built capacity in the U.S. in the short term. As policies continue to change, MNCs' return on investment and implementation strategies are more likely to encounter numerous variables.

However, at present, Trump's tariff policy still forces multinational pharmaceutical companies to seek survival paths in the gap between political cycles and industry rules. Industry insiders say that if this capacity migration of over 200 billion US dollars is successfully implemented, it may promote the formation of a new supply chain segmentation model: "Made in America for America, R&D in Europe, and Manufacturing in Asia."

This shift of production capacity back to the United States will also have a profound impact on the entire Asian market as well as the domestic market. For China-based CDMO companies that rely on exports, there is no doubt that they need to reassess and adjust their strategic direction. For multinational pharmaceutical companies, the ability to adapt to new rules is becoming more urgent than developing new drugs. For participants in the Asian supply chain, this migration is both a crisis and a historical opportunity to reshape the global value chain.